Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

J. M. Donovan, K. Von Bergmann, K. D R Setchell, J. Isaacsohn, Anuradha Pappu, D. R. Illingworth, T. Olson, S. K. Burke

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P <0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P <0.05) and +316% (P <0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P <0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.

Original languageEnglish (US)
Pages (from-to)1232-1238
Number of pages7
JournalDigestive Diseases and Sciences
Volume50
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Sterols
Hypercholesterolemia
Bile Acids and Salts
Cholesterol
LDL Cholesterol
Mevalonic Acid
Polymers
Fatty Acids
Colesevelam Hydrochloride
Diet
Education
Serum

Keywords

  • Bile acid sequestrant
  • Cholesterol
  • Colesevelam
  • Hypercholesterolemia
  • Low-density lipoprotein

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Donovan, J. M., Von Bergmann, K., Setchell, K. D. R., Isaacsohn, J., Pappu, A., Illingworth, D. R., ... Burke, S. K. (2005). Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Digestive Diseases and Sciences, 50(7), 1232-1238. https://doi.org/10.1007/s10620-005-2765-8

Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. / Donovan, J. M.; Von Bergmann, K.; Setchell, K. D R; Isaacsohn, J.; Pappu, Anuradha; Illingworth, D. R.; Olson, T.; Burke, S. K.

In: Digestive Diseases and Sciences, Vol. 50, No. 7, 07.2005, p. 1232-1238.

Research output: Contribution to journalArticle

Donovan, JM, Von Bergmann, K, Setchell, KDR, Isaacsohn, J, Pappu, A, Illingworth, DR, Olson, T & Burke, SK 2005, 'Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia', Digestive Diseases and Sciences, vol. 50, no. 7, pp. 1232-1238. https://doi.org/10.1007/s10620-005-2765-8
Donovan, J. M. ; Von Bergmann, K. ; Setchell, K. D R ; Isaacsohn, J. ; Pappu, Anuradha ; Illingworth, D. R. ; Olson, T. ; Burke, S. K. / Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. In: Digestive Diseases and Sciences. 2005 ; Vol. 50, No. 7. pp. 1232-1238.
@article{670a2bdbc6a14c66945c20d3451c6d68,
title = "Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia",
abstract = "Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10{\%} (P <0.01) and 13{\%} (P = 0.05), mean total cholesterol levels decreased by 4.9{\%} (P = 0.05) and 6.1{\%} (P = 0.09), and total fecal bile acid excretion showed median changes of +324{\%} (P <0.05) and +316{\%} (P <0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P <0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.",
keywords = "Bile acid sequestrant, Cholesterol, Colesevelam, Hypercholesterolemia, Low-density lipoprotein",
author = "Donovan, {J. M.} and {Von Bergmann}, K. and Setchell, {K. D R} and J. Isaacsohn and Anuradha Pappu and Illingworth, {D. R.} and T. Olson and Burke, {S. K.}",
year = "2005",
month = "7",
doi = "10.1007/s10620-005-2765-8",
language = "English (US)",
volume = "50",
pages = "1232--1238",
journal = "American Journal of Digestive Diseases and Nutrition",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "7",

}

TY - JOUR

T1 - Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

AU - Donovan, J. M.

AU - Von Bergmann, K.

AU - Setchell, K. D R

AU - Isaacsohn, J.

AU - Pappu, Anuradha

AU - Illingworth, D. R.

AU - Olson, T.

AU - Burke, S. K.

PY - 2005/7

Y1 - 2005/7

N2 - Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P <0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P <0.05) and +316% (P <0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P <0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.

AB - Colesevelam HCl is a potent bile acid-binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In an apparent dose-related manner, respective mean serum concentrations HCl of low-density lipoprotein cholesterol decreased by 10% (P <0.01) and 13% (P = 0.05), mean total cholesterol levels decreased by 4.9% (P = 0.05) and 6.1% (P = 0.09), and total fecal bile acid excretion showed median changes of +324% (P <0.05) and +316% (P <0.05). Colesevelam HCl did not affect fecal neutral sterol or fecal fatty acid excretion; however, 24-hr urinary mevalonic acid levels significantly increased in both treatment groups (P <0.05). The cholesterol-lowering action of colesevelam HCl appears to be mediated through increased bile acid excretion.

KW - Bile acid sequestrant

KW - Cholesterol

KW - Colesevelam

KW - Hypercholesterolemia

KW - Low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=23044439087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044439087&partnerID=8YFLogxK

U2 - 10.1007/s10620-005-2765-8

DO - 10.1007/s10620-005-2765-8

M3 - Article

C2 - 16047465

AN - SCOPUS:23044439087

VL - 50

SP - 1232

EP - 1238

JO - American Journal of Digestive Diseases and Nutrition

JF - American Journal of Digestive Diseases and Nutrition

SN - 0163-2116

IS - 7

ER -